7. REFERENCES
(1) Neuhaus P, Klupp J, Langrehr J M. mTOR Inhibitors: An
Overview. Liver Transpl. 2001;7(6):473-84.
https://doi.org/10.1053/jlts.2001.24645
(2) Shen L-J, Lin Wu F-L. Nanomedicines in renal transplant rejection-
focus on sirolimus. Int. J Nanomedicine, 2007;2(1):25-32.
https://doi.org/10.2147/nano.2007.2.1.25
(3) Mahalati K, Kahan BD. Clinical Pharmacokinetics of sirolimus.Clin. Pharmacokinet. 2001;40:573-585.
https://doi.org/10.2165/00003088-200140080-00002
(4) Simamora P, Alvarez J M, Yalkowsky S H. Solubilization of Rapamycin.Int J Pharm. 2001;213(1-2):25-9.
https://doi.org/10.1016/s0378-5173(00)00617-7
(5) Sun M, Si L, Zhai X, et.al. The Influence of Co-Solvents on the
Stability and Bioavailability of Rapamycin Formulated in
Self-Microemulsifying Drug Delivery Systems. Drug Dev Ind Pharm.2011;37(8):986-94. https://doi.org/10.3109/03639045.2011.553618
(6) Grinfield A A, Caufield C E, Schiksnis R A, Mattes J F, Chan K W.
Acid Catalyzed Functionalization of rapamycin. Tetrahedron Lett.1994;35(37):6835-6838.
https://doi.org/10.1016/0040-4039(94)85017-8
(7) Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert H-H.J Ocul Pharmacol Ther. 2007;23(3):292-303.
https://doi.org/10.1089/jop.2006.130
(8) Lloberas N, Torras J, Aplerovich G, Cruzado J M, et.al. Different
renal toxicity profiles in the association of cyclosporine and
tacrolimus with sirolimus in rats. Nephrol Dial Transpl.2008;23(10):3111-3119. https://doi.org/10.1093/ndt/gfn223
(9) Nguyen Q D, Ibrahim M A, Watters A, et.al. Ocular Tolerability and
Efficacy of Intravitreal and Subconjunctival Injections of Sirolimus in
Patients With Non-Infectious Uveitis: Primary 6-month Results of the
SAVE study. J Ophthalmic Inflamm Infect . 2013;3(1):32.
https://doi.org/10.1186/1869-5760-3-32
(10) Dugel P U, Blumenkranz M S, Haller J A, et.al. A Randomized,
Dose-Escalation Study of Subconjunctival and Intravitreal Injections of
Sirolimus in Patients With Diabetic Macular Edema. J Ophtalmol.2012;119(1):124-31. https://doi.org/10.1016/j.ophtha.2011.07.034
(11) Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Nida Sen H.
Subconjunctival Sirolimus in the Treatment of Autoimmune Non-Necrotizing
Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J
Ophtalmol. 2015;159(3):601-6.
https://doi.org/10.1016/j.ajo.2014.12.009
(12) Shah M, Edman M C, Janga S R, et.al. A Rapamycin-Binding Protein
Polymer Nanoparticle Shows Potent Therapeutic Activity in Supressing
Autoimmune Dacryoadenitis in a Mouse Model of Sjogren´s Syndrome.J Control Release. 2013;171(3):269-79.
https://doi.org/10.1016/j.jconrel.2013.07.016
(13) Kahan B D. Sirolimus: A Comprehensive Review. Expert Opin
Pharmacother. 2001;2(11):1903-17
(14) Douglas LC, Yi N Y, Davis J L, Salmon J H, Gilger B C, Ocular
Toxicity and Distribuition of Subconjunctival and Intravitreal Rapamycin
in Horses. J Vet Pharmacol Ther. 2008;31(6):511-6.
https://doi.org/10.1111/j.1365-2885.2008.00986.x
(15) De Almeida Manzano R P, Peyman G A, Khan P, et.al. Testing
Intravitreal Toxicity of Rapamycin in Rabbit Eyes. Arq Bras
Oftalmol. 2009;72(1):18-22.
https://doi.org/10.1590/s0004-27492009000100004
(16) WR Gombotz, B.5- Liposomes A2- Ratner, Buddy D, in: A.S Hoffman,
F.J Schoen, J.E Lemons (Eds.), Biomaterials Science (Third Edition),
Academic Press 2013, pp. 1039-1041.
(17) Patel P B, Shastri D H, Shelat P K, Shukla A K. Ophthalmic Drug
Delivery System: Challenges and Approaches. Sys Rev Pharm.2010;1(2):113-120.
(18) Pattni B S, Chupin V V, Torchilin V P. New developments in
Liposomal Drug Delivery. Chem Rev . 2015;115(19):10938-66.
https://doi.org/10.1021/acs.chemrev.5b00046
(19) Kaur I P, Garg A, Singla A K, Aggarwal D. Vesicular Systems in
Ocular Drug Delivery: An Overview. Int J Pharm. 2004;269(1):1-14.
https://doi.org/10.1016/j.ijpharm.2003.09.016
(20) Meisner D, Mezei M. Liposome ocular delivery systems. Adv
Drug Deliv Rev. 1995;16(1):75-93.
https://doi.org/10.1016/0169-409X(95)00016-Z
(21) Bourlais C L, Acar , Zia H, Sado P A, Needham T, Leverge R.
Ophthalmic Drug Delivery Systems—Recent Advances. Prog Retin Eye
Res. 1998;17(1):33-58.
https://doi.org/10.1016/s1350-9462(97)00002-5
(22) Barza M, Baum J, Tremblay C, Szoka F, D´Amico D J. Ocular Toxicity
of Intravitreally Injected Liposomal Amphotericin B in Rhesus Monkeys.Am J Ophtlamol. 1985;100(2):259-63.
https://doi.org/10.1016/0002-9394(85)90791-3
23) M R Mozafari, C J Reed, C Rostron. Cytotoxicity evaluation of
anionic nanoliposomes and nanolipoplexes prepared by the heating method
without employing volatile solvents and detergents.” Pharmazie2007;62(3):205-9. PMID: 17416197
(24)
Linares-Alba M A, Gómez-Guajardo M
B, Furtado-Fonzar J, Brooks D E, García-Sánchez G A, Bernad-Bernad M J.
Preformulation Studies of a Liposomal Formulation Containing Sirolimus
for the Treatment of Dry Eye Disease. J Ocul Pharmacol Ther.2016;32(1):11-22.
https://doi.org/10.1089/jop.2015.0032
(25) García-Sánchez G A, & Bernard M J B. 2017. U.S Patent No.
9,801,862. Washington, DC: U.S. Patent and Trademark Office.
26) Murilo-Bautista A, Nogura-Louzada R, Crunivel Isaac D L,
et.al. In vivo and in vitro toxicity evaluation of liposome-encapsulated
sirolimus. Int. J. Retin. Vitr. 2019; 5(35).
(27) OECD, Test No. 474 Mammalian Erithrocyte Micronucleus Test, OECD
Publishing, 2014
(28) Batista-Duharte A, Murillo G J, Pérez U M, et.al. The Hen´s Egg
Test on Chorioallantoic Membrane: An Alternative Assay for the Assesment
of the Irritating Effect of Vaccine Adjuvants. Int J Toxicol.2016;35(6):627-633. https://doi.org/10.1177/1091581816672187
(29) FEUM, Prueba de pirógenos, in: FEUM (Ed.), Suplemento de
dispositivos médicos, Secretaría de Salud, México 2001.
(30) Demircigil G C, Aykanat B, Fidan K, et.al. Micronucleus Frequencies
in Peripheral Blood Lymphocytes of Children With Chronic Kidney Disease.Mutagenesis . 2011;26(5):643-50.
https://doi.org/10.1093/mutage/ger027
(31) Kempen J H, Gangaputra S, Helzlsouer K J. Long-term risk of
malignancy among patients treated with immunosuppressive agents for
ocular inflammation: A critical assesment of evidence. Am J
Ophtalmol. 2008;146(6):802-12.
https://doi.org/10.1016/j.ajo.2008.04.035
(32) Blagosklonny M V. Molecular Damage in Cancer: An Argument for
mTOR-driven Aging. Aging (Albany NY). 2011;3(12):1130-41.
https://doi.org/10.18632/aging.100422
(33) Tavaszi J, Budai P. The Use of HET-CAM Test in Detecting Ocular
Irritation. Commun Agric Apll Biol Sci. 2007;72(2):137-41.
(34) Parnham M J, Wetzig H. Toxicity Screening of Liposomes. Chem
Phys Lipids. 1993:64(1-3):263-74.
https://doi.org/10.1016/0009-3084(93)90070-j
(35) Food and Drug Administration Center for Veterinary Medicine (2008).
Guidance for Industry: Target Animal Safety for Veterinary
Pharmaceutical Products. VICH GL43.
(36) Shah M, Edman M C, Janga S R, et.al. Rapamycin Eye Drops Suppress
Lacrimal Gland Inflammation In a Murine Model of Sjogren´s Syndrome.Invest Ophthalmol Vis Sci. 2017;58(1):372-385.
https://doi.org/10.1167/iovs.16-19159
(36) H.L. Ioachim, L.J. Medeiros,
Ioachim’s Lymph Node Pathology, Wolters Kluwer Health/Lippincott
Williams & Wilkins2009.
(37) S.W. Barthold, S.M. Griffey,
D.H. Percy, Pathology of Laboratory Rodents and Rabbits, Wiley2016.
(38) Sunohara-Neilson J, Brash M, Carman S, Nagy E, Turner P V.
Experimental Infection of New Zealand White Rabbits (Oryctolagus
cuniculi) with Leporid herpesvirus 4. Comp Med.2013;63(5):422-430. PMID 24210019
(39) P.J. Manning, D.H. Ringler, C.E.
Newcomer, The Biology of the Laboratory Rabbit, Elsevier Science2014.
(40) Erdine S, Yucel A, Ozyalçin, et.al. Neurotoxicity of Midazolam in
the Rabbit. Pain. 1999;80(1-2):419-23.
https://doi.org/10.1016/s0304-3959(98)00240-1
(41) Cox J C, Hamilton R C, Attwood H D. An Investigation of the Route
and Progression of Encephailtozzon Cuniculi Infection in Adult Rabbits.J Protozool. 1979;26(2):260-5.
https://doi.org/10.1111/j.1550-7408.1979.tb02776.x.
(42) Pellett, Sarah. ”Encephalitozoon cuniculi in rabbits: an overview.”Companion Animal 21.5 (2016): 300-305.
(43) Kunzel F, Joachim A. Encephalitozoonosis in Rabbits.Parasitol Res. 2010;106(2):299-309.
https://doi.org/10.1007/s00436-009-1679-3
(44) Cox J C, Gallichio H A. Serological and Histological Studies on
Adult Rabbits With Recent, Naturally Acquired Encephalitozoonosis.Res Vet Sci. 1978;24(2):260-1. PMID:653124
(45) Everds N E, Snyder P W, Bailey K L. Interpreting Stress Responses
During Routine Toxicity Studies: A Review of the Biology, Impact, and
Assessment. Toxicol Pathol. 2013;41(4):560-614.
https://doi.org/10.1177/0192623312466452
46) Özkan Ö, Alcigir ME. Subacute Stage of Encephalitozoon
cuniculi Infection in Eye Lesions of Rabbit in Turkey. Iran J
Parasitol . 2018;13(2):301-309.
(47) Morrisett J D, Abdel-Fattah G, Hoogeveen R, et.al. Effects of
Sirolimus on Plasma Lipids, Lipoprotein Levels, and Fatty Acid
Metabolism in Renal Transplant Patients. J Lipid Res.2002;43(8):1170-80. PMID:12177161
(48) Falke L L, van Vuuren S H, Kazazi-Hyseni F, et.al. Local
Therapeutic Efficacy With Reduced Systemic Side Effects by
Rapamycin-Loaded Subcapsular Microspheres. Biomaterials.2015;42:151-60. https://doi.org/10.1016/j.biomaterials.2014.11.042
(49) Aguirre S A, Gukasyan H J, Younis H S, Huang W. Safety Assessment
of Formulation Vehicles Following Intravitreal Administration in
Rabbits. Pharm Res. 2018;35(9):173.
https://doi.org/10.1007/s11095-018-2450-1
(50) Mochizuki K, Torisaki M, Kawasaki K. Retinal toxicity of
antibiotics: Evaluation by electroretinogram. Doc Ophthalmol.1988;69:195-202
(51) Patel S, Barnett J M, Kim S J. Retinal Toxicity of Intravitreal
Polyethylene Glycol 400. J Ocul Pharmacol Th. 2016;32(2).
https://doi.org/10.1089/jop.2015.0069
(52) Brandao-De Paiva M R, Almeida-Lage N, Andrade M C, et.al. Toxicity
and in Vivo Release Profile of Sirolimus From Implants Into the Vitreous
of Rabbits´Eyes. Doc Ophthalmol. 2019;138(1):3-19.
https://doi.org/10.1007/s10633-018-9664-8
(53) Okamoto T, Ozawa Y, Kamoshita M. The Neuroprotective Effect of
Rapamycin as a Modulator of the mTOR-NF-κB Axis During Retinal
Inflammation. PLoS One. 2016;11(1):e0146517.
https://doi.org/10.1371/journal.pone.0146517.